Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ′easy to apply′ probability models

被引:9
作者
Bodmer, D.
Ligtenberg, M. J. L.
van der Hout, A. H.
Gloudemans, S.
Ansink, K.
Oosterwijk, J. C.
Hoogerbrugge, N.
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[3] Univ Groningen, Med Ctr, Dept Clin Genet, NL-9700 RB Groningen, Netherlands
关键词
breast cancer; ovarian cancer; BRCA1; BRCA2; mutation; probability model;
D O I
10.1038/sj.bjc.6603306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To establish an efficient, reliable and easy to apply risk assessment tool to select families with breast and/or ovarian cancer patients for BRCA mutation testing, using available probability models. In a retrospective study of 263 families with breast and/or ovarian cancer patients, the utility of the Frank (Myriad), Gilpin (family history assessment tool) and Evans ( Manchester) model was analysed, to select 49 BRCA mutation-positive families. For various cutoff levels and combinations, the sensitivity and specificity were calculated and compared. The best combinations were subsequently validated in additional sets of families. Comparable sensitivity and specificity were obtained with the Gilpin and Evans models. They appeared to be complementary to the Frank model. To obtain an optimal sensitivity, five 'additional criteria' were introduced that are specific for the selection of small or uninformative families. The optimal selection is made by the combination 'Frank >= 16% or Evans2 >= 12 or one of five additional criteria'. The efficiency of the selection of families for mutation testing of BRCA1 and BRCA2 can be optimised by using a combination of available easy to apply risk assessment models.
引用
收藏
页码:757 / 762
页数:6
相关论文
共 22 条
[1]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[2]  
Bermejo JL, 2004, ANN ONCOL, V15, P1834, DOI [10.1093/annone/mdh474, 10.1093/annonc/mdh474]
[3]   BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [J].
Berry, DA ;
Iversen, ES ;
Gudbjartsson, DF ;
Hiller, EH ;
Garber, JE ;
Peshkin, BN ;
Lerman, C ;
Watson, P ;
Lynch, HT ;
Hilsenbeck, SG ;
Rubinstein, WS ;
Hughes, KS ;
Parmigiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2701-2712
[4]   Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ [J].
Claus, EB ;
Petruzella, S ;
Matloff, E ;
Carter, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (08) :964-969
[5]   Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history [J].
Claus, EB ;
Schildkraut, J ;
Iversen, ES ;
Berry, D ;
Parmigiani, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (23) :1824-1829
[6]   Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics [J].
de la Hoya, M ;
Díez, O ;
Pérez-Segura, P ;
Godino, J ;
Fernández, JM ;
Sanz, J ;
Alonso, C ;
Baiget, M ;
Díaz-Rubio, E ;
Caldés, T .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (07) :503-510
[7]   Application of breast cancer risk prediction models in clinical practice [J].
Domchek, SM ;
Eisen, A ;
Calzone, K ;
Stopfer, J ;
Blackwood, A ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :593-601
[8]   Update on the Manchester scoring system for BRCA1 and BRCA2 testing -: art. no. e39 [J].
Evans, DGR ;
Lalloo, F ;
Wallace, A ;
Rahman, N .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (07)
[9]   A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO [J].
Evans, DGR ;
Eccles, DM ;
Rahman, N ;
Young, K ;
Bulman, M ;
Amir, E ;
Shenton, A ;
Howell, A ;
Lalloo, F .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (06) :474-480
[10]   Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2:: Analysis of 10,000 individuals [J].
Frank, TS ;
Deffenbaugh, AM ;
Reid, JE ;
Hulick, M ;
Ward, BE ;
Lingenfelter, B ;
Gumpper, KL ;
Scholl, T ;
Tavtigian, SV ;
Pruss, DR ;
Critchfield, GC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1480-1490